Spots Global Cancer Trial Database for Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer
Official Title: Phase II Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer
Study ID: NCT00511446
Conditions
Interventions
Study Description
Brief Summary: Combination regimens of 3 active drugs have shown promising activity in treatment of metastatic gastric cancer. Docetaxel combined with cisplatin and 5-fluorouracil (FU) yielded superior overall survival and response rates when compared to standard cisplatin and 5-FU. However, a toxicity profile showed the need for development of less toxic modifications. In a prior phase I trial, the maximum tolerated dose was defined. In this phase II trial, a first evaluation of activity will be performed.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Charite - Universitatsmedizin Berlin, Berlin, , Germany
Medizinische Universitätsklinik - Knappschaftskrankenhaus, Bochum, , Germany
Städtische Kliniken Esslingen, Esslingen, , Germany
MVZ Osthessen, Fulda, , Germany
Martin-Luther-University Halle-Wittenberg, Halle (Saale), , Germany
Städt. Klinikum St. Georg, Leipzig, , Germany
OSP Lörrach-Rheinfelden, Lörrach, , Germany
Universitätsklinikum Mainz, Mainz, , Germany
Universitätsklinikum Mannheim, Mannheim, , Germany
Universitätsklinik Ulm, Ulm, , Germany
Contact Details
Name: Hans-Joachim Schmoll, Prof. Dr.
Affiliation: Martin-Luther-University Halle-Wittenberg, Medical Faculty
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
